small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search

Capabilities 44 results

Practice Area

Antitrust/Competition

Practice Area

Class Actions & Group Litigation

Winston has developed a consistent record of success handling class action cases in state and federal courts. The practice is anchored by seasoned class action lawyers, many of whom have been recognized by Chambers USA and other ranking organizations as being top practitioners in their field. Our clients rely on us to steer them through class action matters by drawing on the firm’s significant experience in resolving complex litigation using creative and aggressive arguments, across a broad range of class, collective, coordinated, and mass actions, as well multidistrict litigation. We also have succeeded at trial in several class actions—a rare occurrence....Read more

Industry

Life Sciences

Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations....Read more

Experience 118 results

Experience

|

March 18, 2026

Winston & Strawn LLP Advises Maxim Group LLC on $100 Million IPO of BHAV Acquisition Corp

Winston & Strawn LLP represented the underwriter, Maxim Group LLC, in connection with the $100 million initial public offering of BHAV Acquisition Corp. The offering consisted of 10,000,000 units priced at $10.00 per unit, with each unit comprising one Class A ordinary share and one right. Each right entitles the holder to receive one-fourth (1/4) of one Class A ordinary share upon the consummation of the Company’s initial business combination....Read more

Experience

|

March 16, 2026

Winston & Strawn Advises D. Boral Capital on $120 Million IPO of Pono Capital Four, Inc.

Winston & Strawn LLP served as counsel to D. Boral Capital LLC in connection with the $120 million initial public offering of Pono Capital Four, Inc.. The offering was led by D. Boral Capital LLC as sole book-running manager and consisted of 12,000,000 units priced at $10.00 per unit....Read more

Experience

|

March 6, 2026

Transition Evergreen & Zencap Agreement: Winston Advises Transition Evergreen on Its Restructuring

Transition Evergreen, a company listed on Euronext Paris and dedicated to ecological transition and carbon-footprint reduction, has completed the first phase of its financial restructuring by carrying out, on February 26 and 27, 2026, the operations set out in a settlement agreement concluded with its main creditor, a private debt fund managed by Zencap Asset Management (“Zencap”)....Read more
View All Experience

Insights & News 858 results

Product Liability & Mass Torts Digest

|

April 3, 2026

|

8 Min Read

A Recipe for Exclusion: Why the Baby Food MDL Experts Failed Under Daubert

In a high-stakes decision on expert exclusion authored late last month, the District Court for the Northern District of California granted defendants’ motion to exclude plaintiffs’ general causation expert witnesses in In re Baby Food Products Liability Litigation—a consolidated mass tort of over 100 pending cases regarding the alleged presence of toxic heavy metals in baby food.

Client Alert

|

March 31, 2026

|

4 Min Read

The Xerox “Non-Subsidiary Drop-Down Financing”: A New Frontier in Leakage and Subordination?

Last month, Xerox Corporation (Xerox) completed a $450 million intellectual property-backed financing through a newly formed joint venture with third-party private equity investors. The transaction has drawn considerable attention among leveraged finance participants and practitioners as it exposes a potential structural gap found in many of today’s credit documents....Read more

Non-Fungible Insights: Blockchain Decrypted

|

March 26, 2026

|

6 Min Read

FCA Handbook Application for Regulated Cryptoasset Activities – Key Takeaways from CP26/4

The close of 2025 highlighted the continuing momentum for the digital asset industry, with regulatory developments accelerating rather than slowing.

View All Insights & News

Other Results 32 results

Site Content

What Is the Price Range in an IPO?

The price range is a proposed price per share range for the IPO within which investors can bid for shares and which is often printed on the cover page of a preliminary prospectus. The price range has a minimum price, known as the floor price, and a maximum price, known as the cap price....Read more

Site Content

What Is the BPCIA?

Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) to provide an abbreviated pathway for biosimilars to gain FDA approval through submission of an abbreviated Biologics License Application (aBLA)....Read more

Site Content

What Is Dilution?

Dilution refers to the reduction in an existing shareholder’s ownership percentage of a company when the company issues additional shares. Dilution in an IPO results from a disparity between the public offering price in an IPO and the effective cash cost to persons who acquired shares prior to the IPO. Dilution is disclosed in the registration statement in a dilution table....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2026. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising